Aegerion Pharmaceuticals, Inc. AEGR, a biopharmaceutical company dedicated
to the development and commercialization of innovative, life-altering
therapies for patients with debilitating and often fatal rare diseases,
today announced that on April 1, 2013, Aegerion granted stock options to
purchase an aggregate of 13,000 shares of common stock to two new employees
under the inducement stock option program described below. Each stock option
has an exercise price per share equal to $39.02, the closing price of
Aegerion's common stock on the grant date; vests in equal monthly
installments over four years; has a ten year term; and is subject to the
terms and conditions of Aegerion's Inducement Award Stock Option Plan, and
the terms and conditions of a stock option agreement covering the grant.
As Aegerion previously announced, in support of the company's build of its
U.S. commercial organization and international expansion, the Compensation
Committee of the Company's Board of Directors approved the reservation of
1,000,000 shares of common stock to be used exclusively for the grant of
non-qualified stock options to individuals who were not previously an
employee or non-employee director of Aegerion (or following a bona fide
period of non-employment), as an inducement new hire stock option award
material to an individual's entry into employment within the meaning of Rule
5635(c)(4) of the NASDAQ Listing Rules (Inducement Stock Options).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in